Member Info for Vascular

High mp12345,

I cant find anything exclusively mentioning NHS either but i do recall this from the withdraw from Plantir supplying technology to NHS a month or so ago

"The UK government has promised a different approach to tech procurement following the award of controversial contracts to Palantir. Speaking to MPs, science minister Patrick Vallance said that the government's deals with Palantir – which has large contracts with the NHS and the Ministry of Defence – would be done differently in the future, instead emphasizing investment in UK technology and companies."

GL Vas

Out today. An explanation form FDBk's sale manager one of one of the Health Departments key targets and how FDBK can help them achieve this.

Just need the actual sales now...and we will be smiling.

Any sign of the slightest news here and i expect some kind of fireworks, followed by a celebratory Bank Holiday and a fly over from the Blue Arrows plus a quick 60% instant surge in the sp, just to start with.

https://www.linkedin.com/posts/feedback-medical-ltd_whilst-leftward-shift-and-moving-care-into-activity-7465031514255450113-dDJP

If you read MHRA Results and Forecast 2025/26 | 2026/27. It reads as if they are doing very well in achieving all there KPIs, up until March 2026.

example : KPI heading : Clinical trial and clinical investigation applications assessed on time = 100%

I can think of one company still waiting and begs the question what does assessed on time mean ?

https://assets.publishing.service.gov.uk/media/69eb701dd36883a64473b993/MHRA_Impact_Report_25_26_27.pdf

https://assets.publishing.service.gov.uk/media/69eb701dd36883a64473b993/MHRA_Impact_Report_25_26_27.pdf

Apologies of. Bringing up old info.

But an Interesting comparison between Scancell the company in April 2023 , when this Viulpes internal investment note was published and the Scancell of Today along with all the subsequent achievements made by the company since.

The share price on 17th April 23 was 18.5p, …..4p less than Today!

vulpes stated

“ Valuation: We view the current share price as derisory; reflective of poor market sentiment for biotech stocks and the early-stage nature of the business, with management too focused on the science, rather than medium- and long-term commercial aspects”

So , today’s share price has not priced in the last three years achievements ( specifically the science / trial results) , the transformative in commercial opportunities, with the company’s actively searching for partnership funding , Nasdak etc plus the ever present unknown …could be a surprise sale of one or more of the four platforms.

https://vulpesinvest.com/life-sciences/scancell-holdings-plc-multiple-arrows-in-its-quiver/

Your welcome Chester.

Wildforce. I think you are correct about AIM not having a clue how to value Scancell. Pharma plays v. Difficult to value in the early stages. In many ways, from an investment point of view it’s worked in my, and many investors favour , being able to accumulate shares over the years at what will hopefully be seen sometime soonish as crazily low prices ! Sometime in the future , someone is going to value Scancell and pay what it’s actually worth. That will be the value, and our pay day.

One of the good things about being a scancell investor is that if I do well in my investment, this will be because Scancell would have improved standard of care and so it’s not just investors who win here, everyone wins looking forward…especially if your unlucky enough are diagnosed with a cancer. Pretty much go hand in hand imo.

Does this help Chester.

https://www.oncologynewscentral.com/conference-news/immunotherapy-combination-provides-limited-pfs-benefit-in-advanced-melanoma

Hi Cleanworld and All

I’m invested and wondering why after so much Talk/ investigation/ confidential data being shared under NDA etc with many large potential pharma company’s looking to partner with Scancell ….then these company’s must “ get it” , the opportunity's here , the potential size of the matket her, a new market, the threat to their own offerings etc etc more so than most of us here , so why has there been no all out, takeover of Scancell to take advantage of the unique IP, and protect future revenues……hardly a day goes by without an example posted here for multi billion dollar deals for company’s , non revenue company’s

with seemingly far less potential ……if what we believe scancell is Capable of accurate then this knowledge will defo be in the pharma industry by now….why no knock out takeover to grab the IP and future platforms while still available. A few billion now , to secure tens of billions later mentality. Isn’t that how pharma works normally. Why not here? GL vas and thanks for all your excellent posts.

All this drama...!

The dramatic rise, the fall back to take some profit and shortly, hopefully the second attempt at 27p....and we have not even had any news yet!!!

Long way to go yet....

Page 9

https://scancell.co.uk/wp-content/uploads/2024/11/agm-october-2024.pdf

Professor Poulam Patel was a principle investigator at Nottingham University site on the Scope study.

Page 9

“ Last month Scancell (SCLP) announced that it had received FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provided a data update from its SCOPE Phase 2 study. Since then we have had no fresh news, yet the shares have rocketed. Presumably there is fresh news on the way, and a further re-rate for the developer of active immunotherapies to treat cancer.”

https://www.share-talk.com/traders-cafe-with-zak-mir-the-week-in-small-caps-sunday-17th-may-2026/

Looking back, the company sp had a year high of 38p on the 28th May 25

What’s changed? Everything ! , as the company has transformed itself, and is in a much better position than a year ago and presently at 22p.

Optum uk bought

https://www.digitalhealth.net/2026/05/gp-it-supplier-optum-acquired-by-us-equity-firm-tpg/

How much bad luck can one company have? I'm not sure what effect , if any the Heath Minister stepping down could cause, but its not the good news i was hoping for. There is no way Tom et al could have foreseen this move, along with the delay in procurement to end of year news announced a while ago.

Hope something comes up for them as they ( and we) deserve a break imo

Good to be in early, hopefully some news on the way sometime soonish ... shame about that ugly spread!

Excellent observatiion from ChillTime.

Maybe someone should share on other pharma boards….its not as if it would do any harm to the current investors, company or the sp!

I hope they drop some positive news soon …., just a taster! If only to get us through the summer.

Thanks Johnny.

Interesting read and explanation about ctDNA. After reading this I can see the connection highlighted by scancell.

https://www.urologytimes.com/view/bladder-cancer-awareness-month-the-rise-of-biomarkers-and-precision-care

Hi Darkcorner.

I, probably like yourself Just waiting for cash flow positivity from end of Q2. If delivered, as management have stated in last RNS then the this will give credible assurances of a turnaround and sp should rerate significantly imo .

Hoping for one or more significant new contract wins meanwhile. gL vas

Anyone thinking some kind of funding deal has now been agreed. And with this in mind Phills recent comment " moving forward at pace" was made ?

If no funding deals had been agreed..and with no cerrtainty of how funding will fall..would phil have made this comment . It's H2 in a few weeks.!!.